{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:46:31Z","timestamp":1782762391044,"version":"3.54.5"},"update-to":[{"DOI":"10.12688\/wellcomeopenres.17505.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000}},{"DOI":"10.12688\/wellcomeopenres.17505.2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000}}],"reference-count":30,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/18\/4\/34215"],"award-info":[{"award-number":["RE\/18\/4\/34215"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["200990\/A\/16\/Z"],"award-info":[{"award-number":["200990\/A\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["107469"],"award-info":[{"award-number":["107469"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220119"],"award-info":[{"award-number":["220119"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["wellcomeopenresearch.org"],"crossmark-restriction":false},"short-container-title":["Wellcome Open Res"],"abstract":"<ns3:p><ns3:bold>Background: <\/ns3:bold>Taurine, 2-aminoethanesulfonic acid, is an amino acid found in animal products. Taurine is produced for human consumption as a supplement and ingredient in beverages. Supplementation is a safe, inexpensive, and effective treatment for dilated cardiomyopathy (DCM) in domestic mammals, however it is currently unlicensed in Europe and the United States for human medical treatment. Recent genome-wide association studies of DCM have identified the locus of the taurine transporter (<ns3:italic>SLC6A6<\/ns3:italic>). To assess whether taurine supplementation may be a novel therapeutic option for DCM, we undertook a systematic review.<\/ns3:p><ns3:p> <ns3:bold>Methods: <\/ns3:bold>Four electronic databases (PubMed, Cochrane Central Register, Web of Science, Biomed Central) were searched until 11\/03\/21. Included studies of human participants reported measured phenotypes or symptoms for cardiomyopathy, heart failure (HF), or altered left ventricle structure or function, administering taurine in any formulation, by any method. Non-English articles were excluded. Meta-analysis was completed in R software (version 3.6.0). The Newcastle-Ottawa Scale quality assessment score (NOQAS) tool was used to assess bias.<\/ns3:p><ns3:p> <ns3:bold>Results: <\/ns3:bold>285 articles were identified, of which eleven met our criteria for inclusion. Only one paper was deemed \u201chigh quality\u201d using the NOQAS tool. Taurine supplementation varied across studies; by dose (500 mg to 6g per day), frequency (once to thrice daily), delivery method (tablet, capsule, drink, powder), and duration (2 to 48 weeks). Patient inclusion was all-cause HF patients with ejection fraction (EF) &lt;50% and no study was specific to DCM. While improvements in diastolic and systolic function, exercise capacity, and haemodynamic parameters were described, only EF and stroke volume were measured in enough studies to complete a meta-analysis; the association was not significant with all-cause HF (P&lt;0.05). No significant safety concerns were reported.<\/ns3:p><ns3:p> <ns3:bold>Conclusions: <\/ns3:bold>A formal clinical trial is needed to address whether taurine supplementation is beneficial to the approximately 1\/250 individuals with DCM in the population.<\/ns3:p>","DOI":"10.12688\/wellcomeopenres.17505.3","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T12:50:09Z","timestamp":1657198209000},"page":"9","update-policy":"https:\/\/doi.org\/10.12688\/wellcomeopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review"],"prefix":"10.12688","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5445-6906","authenticated-orcid":false,"given":"Kathryn A.","family":"McGurk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Kasapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-5880","authenticated-orcid":false,"given":"James S.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1850-1858","DOI":"10.1093\/eurheartj\/ehv727","article-title":"Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases.","volume":"37","author":"Y Pinto","year":"2016","journal-title":"Eur Heart J."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"531-547","DOI":"10.1038\/nrcardio.2013.105","article-title":"Dilated cardiomyopathy: The complexity of a diverse genetic architecture.","volume":"10","author":"R Hershberger","year":"2013","journal-title":"Nat Rev Cardiol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"241-252","DOI":"10.1038\/nrcardio.2017.190","article-title":"Role of titin in cardiomyopathy: From DNA variants to patient stratification.","volume":"15","author":"J Ware","year":"2018","journal-title":"Nat Rev Cardiol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"731-748","DOI":"10.1161\/CIRCRESAHA.116.309396","article-title":"Dilated cardiomyopathy: Genetic determinants and mechanisms.","volume":"121","author":"E McNally","year":"2017","journal-title":"Circ Res."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"2000-2011","DOI":"10.1093\/eurheartj\/ehab030","article-title":"Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.","volume":"42","author":"S Garnier","year":"2021","journal-title":"Eur Heart J."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"128-134","DOI":"10.1038\/s41588-020-00762-2","article-title":"Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect.","volume":"53","author":"R Tadros","year":"2021","journal-title":"Nat Genet."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1318-1330","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues.","volume":"369","author":"F Aguet","year":"2020","journal-title":"Science."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"618-623","DOI":"10.1093\/hmg\/ddz303","article-title":"Taurine treatment of retinal degeneration and cardiomyopathy in a consanguineous family with SLC6A6 taurine transporter deficiency.","volume":"29","author":"M Ansar","year":"2020","journal-title":"Hum Mol Genet."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"549-58","DOI":"10.1007\/s00726-015-2110-2","article-title":"Impaired energy metabolism of the taurine-deficient heart.","volume":"48","author":"S Schaffer","year":"2016","journal-title":"Amino Acids."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"764-768","DOI":"10.1126\/science.3616607","article-title":"Myocardial failure in cats associated with low plasma taurine: A reversible cardiomyopathy.","volume":"237","author":"P Pion","year":"1987","journal-title":"Science."},{"key":"ref-11","first-page":"275-284","article-title":"Response of cats with dilated cardiomyopathy to taurine supplementation.","volume":"201","author":"P Pion","year":"1992","journal-title":"J Am Vet Med Assoc."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"541-547","DOI":"10.1016\/0002-8703(91)90724-v","article-title":"Dietary taurine deficiency and dilated cardiomyopathy in the fox.","volume":"121","author":"N Moise","year":"1991","journal-title":"Am Heart J."},{"key":"ref-13","first-page":"449-458","article-title":"Conditioned nutritional deficiencies in the cardiomyopathic hamster heart.","volume":"17","author":"M Keith","year":"2001","journal-title":"Can J Cardiol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"204-211","DOI":"10.1111\/j.1939-1676.1997.tb00092.x","article-title":"Results of the multicenter spaniel trial (MUST): taurine- and carnitine-responsive dilated cardiomyopathy in American cocker spaniels with decreased plasma taurine concentration.","volume":"11","author":"M Kittleson","year":"1997","journal-title":"J Vet Intern Med."},{"key":"ref-15","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"G Wells"},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"1390-1403","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of Psoriasis with the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis.","volume":"155","author":"A Trafford","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"637-649","DOI":"10.1007\/978-3-319-15126-7_51","article-title":"Use of taurine during rehabilitation after cardiac surgery.","volume":"803","author":"E Averin","year":"2015","journal-title":"Adv Exp Med Biol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"276-282","DOI":"10.1002\/clc.4960080507","article-title":"Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial.","volume":"8","author":"J Azuma","year":"1985","journal-title":"Clin Cardiol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1092-1100","DOI":"10.1067\/mhj.2002.121927","article-title":"Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction.","volume":"143","author":"F Jeejeebhoy","year":"2002","journal-title":"Am Heart J."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"20-26","DOI":"10.1111\/1744-9987.12330","article-title":"Effect of Taurine on Hemodiafiltration in Patients With Chronic Heart Failure.","volume":"20","author":"S Shiohira","year":"2016","journal-title":"Ther Apher Dial."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"95-99","DOI":"10.1253\/jcj.56.95","article-title":"Usefulness of taurine in chronic congestive heart failure and its prospective application.","volume":"56","author":"J Azuma","year":"1992","journal-title":"Jpn Circ J."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"333-337","DOI":"10.1016\/j.jjcc.2011.01.007","article-title":"Effect of taurine supplementation on exercise capacity of patients with heart failure.","volume":"57","author":"M Beyranvand","year":"2011","journal-title":"J Cardiol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"422-432","DOI":"10.1080\/19390211.2016.1267059","article-title":"Taurine Supplementation Improves Functional Capacity, Myocardial Oxygen Consumption, and Electrical Activity in Heart Failure.","volume":"14","author":"M Ahmadian","year":"2017","journal-title":"J Diet Suppl."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"185-194","DOI":"10.1177\/1753944717711138","article-title":"Taurine supplementation has anti-atherogenic and anti-inflammatory effects before and after incremental exercise in heart failure.","volume":"11","author":"M Ahmadian","year":"2017","journal-title":"Ther Adv Cardiovasc Dis."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"425-433","DOI":"10.1007\/978-1-4899-1471-2_46","article-title":"Long-term effect of taurine in congestive heart failure: preliminary report. Heart Failure Research with Taurine Group.","volume":"359","author":"J Azuma","year":"1994","journal-title":"Adv Exp Med Biol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"303-304","DOI":"10.1016\/0167-5273(82)90052-3","article-title":"Taurine for treatment of congestive heart failure.","volume":"2","author":"J Azuma","year":"1982","journal-title":"Int J Cardiol."},{"key":"ref-27","first-page":"P228","article-title":"Evaluation of the effect of taurine supplementation in chronic heart failure patients; a new study on old amino acid.","volume":"Abstracts","author":"S Azab","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"e001368","DOI":"10.1136\/bmjopen-2012-001368","article-title":"Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales.","volume":"2","author":"M Oremus","year":"2012","journal-title":"BMJ Open."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"982-993","DOI":"10.1016\/j.jclinepi.2013.03.003","article-title":"Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers.","volume":"66","author":"L Hartling","year":"2013","journal-title":"J Clin Epidemiol."},{"key":"ref-30","article-title":"kmcgurk\/TaurineDCM: First release (Version v1).","author":"K McGurk","year":"2021","journal-title":"Zenodo."}],"container-title":["Wellcome Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/7-9\/v3\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/7-9\/v3\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/7-9\/v3\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T12:50:15Z","timestamp":1657198215000},"score":1,"resource":{"primary":{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/7-9\/v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":30,"URL":"https:\/\/doi.org\/10.12688\/wellcomeopenres.17505.3","relation":{},"ISSN":["2398-502X"],"issn-type":[{"value":"2398-502X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"Indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/7-9\/v3#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/wellcomeopenres.19584.r48537, Abdallah Al-Mohammad, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK, 07 Mar 2022, version 2, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/7-9\/v2#referee-response-48537","order":0,"name":"referee-response-48537","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/wellcomeopenres.19584.r51169, Alexandra Butters, Joanna Sweeting, Centre for Population Genomics, Garvan Institute of Medical Research and University of New South Wales, Sydney, Australia, 05 Jul 2022, version 2, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/7-9\/v2#referee-response-51169","order":1,"name":"referee-response-51169","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Kathryn McGurk<\/b>; \n<i>Posted: 05 Jul 2022<\/i>; We thank Alexandra Butters and Doctor Joanna Sweeting for taking the time to review this article and for their summary statements.&nbsp;&nbsp; &nbsp; We have added the table to the manuscript, as they suggested.","URL":"https:\/\/wellcomeopenresearch.org\/articles\/7-9\/v3#referee-comment-5046","order":2,"name":"referee-comment-5046","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by the British Heart Foundation Centre of Research Excellence at Imperial College London [RE\/18\/4\/34215 to K.A.M., J.S.W.]; Wellcome [107469; 200990 to J.S.W.; 220119 to M.K.], Medical Research Council (UK), and the NIHR Imperial College Biomedical Research Centre. The views expressed in this work are those of the authors and not necessarily those of the funders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}